A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time

Cancer

Volumn 79, Issue 9, 1997, Pages 1703-1709

  Schmid, Hans Peter ^a,b   Maibach, Rudolf ^a   Bernhard, Juerg ^a   Hering, Franz ^a   Hanselmann, Silvia ^a   Gusset, Heidi ^a   Morant, Rudolf ^a   Pestalozzi, Dietegen ^a   Castiglione, Monica ^a  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

chemotherapy; hormone resistance; idarubicin; prostate carcinoma; prostate specific antigen; prostate specific antigen doubling time; quality of life

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IDARUBICIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IDARUBICIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030965020     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1703::AID-CNCR10>3.0.CO;2-1     Document Type: Article

References (21)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45:8-30.
2. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr. Campbell's urology. 6th edition. Philadelphia: WB Saunders, 1992:1159-221.
3. Eisenberger MA. Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7:151-63.
4. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71:2031-40.
5. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147:931-4.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
7. Aaronson NK, Bakker W, Stewart AL, Van Dam FSAM, Van Zandwijk N, Yarnold JR, et al. Multidimensional approach to the measurement of quality of life in lung cancer clinical trials. In: Aaronson NK, Beckmann J. The quality of life of cancer patients. New York: Raven Press, 1987:101-9.
8. Fossa SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth K-H, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer 1990; 26:1133-6.
9. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590-7.
10. Bernhard J. "Lebensqualitaet" in onkologischen Therapiestudien. Konzepte, Methodik und Anwendung am Beispiel des Kleinzelligen Bronchuskarzinoms. Europaeische Hochschulschriften, Reihe 6, Psychologie, Bd. 380. Bern: Peter Lang Verlag, 1992.
11. Joss RA, Bacchi M, Huerny C, Bernhard J, Cerny T, Martinelli G, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Ann Oncol 1995; 6:157-66.
12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85:365-76.
13. Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn H J, et al. Initial prognostic factors in small cell lung cancer patients predicting quality of life during chemotherapy. Br J Cancer. In press.
14. Nemoto R, Uchida K, Shimazui T, Hattori K, Koiso K, Harada M. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. J Urol 1989; 141:337-40.
15. Scher HI, Yagoda A. Clinical trials in prostatic cancer: methodology and controversies. In: Bruce AW, Trachtenberg J. Adenocarcinoma of the prostate. New York: Springer-Verlag, 1987:197-220.
16. Lopez M, Contegiacomo A, Vivi P, Dello Ioio C, Di Lauro L, Pagliarulo C, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64:2431-6.
17. Madsen EL, Bastholt L, Bertelsen K, Rose C, Nielsen ES, Gadeberg CC. Weekly oral idarubicin in advanced prostatic cancer: a phase II study. Acta Oncol 1992; 31:337-40.
18. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11:607-15.
19. Schmid H-P. Prostate specific antigen doubling time in diagnosis and follow up of patients with prostate cancer. Tumour Marker Update 1996; 8:71-7.
20. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses: the value of a data base in clinical care. Cancer 1994; 73:2791-802.
21. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-64.